CO5200760A1 - Antagonistas del receptor de la il-8 ceptor il-8 - Google Patents
Antagonistas del receptor de la il-8 ceptor il-8Info
- Publication number
- CO5200760A1 CO5200760A1 CO00043844A CO00043844A CO5200760A1 CO 5200760 A1 CO5200760 A1 CO 5200760A1 CO 00043844 A CO00043844 A CO 00043844A CO 00043844 A CO00043844 A CO 00043844A CO 5200760 A1 CO5200760 A1 CO 5200760A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkenyl
- alkyl
- aryl
- heterocyclic
- heteroaryl
- Prior art date
Links
- 108090001007 Interleukin-8 Proteins 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 2
- 108010012236 Chemokines Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 150000001540 azides Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000005024 alkenyl aryl group Chemical group 0.000 abstract 1
- 125000005217 alkenylheteroaryl group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 208000007565 gingivitis Diseases 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 102000010681 interleukin-8 receptors Human genes 0.000 abstract 1
- 108010038415 interleukin-8 receptors Proteins 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13967599P | 1999-06-16 | 1999-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5200760A1 true CO5200760A1 (es) | 2002-09-27 |
Family
ID=22487790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00043844A CO5200760A1 (es) | 1999-06-16 | 2000-06-13 | Antagonistas del receptor de la il-8 ceptor il-8 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1185261A4 (fr) |
| JP (1) | JP2003501459A (fr) |
| KR (1) | KR20020010709A (fr) |
| CN (1) | CN1355697A (fr) |
| AR (1) | AR030391A1 (fr) |
| AU (1) | AU766083B2 (fr) |
| BR (1) | BR0010802A (fr) |
| CA (1) | CA2377341A1 (fr) |
| CO (1) | CO5200760A1 (fr) |
| CZ (1) | CZ20014471A3 (fr) |
| HK (1) | HK1044483A1 (fr) |
| HU (1) | HUP0201571A3 (fr) |
| IL (1) | IL145761A0 (fr) |
| MX (1) | MXPA01013004A (fr) |
| NO (1) | NO20016053L (fr) |
| NZ (1) | NZ514695A (fr) |
| PL (1) | PL352232A1 (fr) |
| TR (1) | TR200103680T2 (fr) |
| WO (1) | WO2000076495A1 (fr) |
| ZA (1) | ZA200109479B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521479B2 (en) * | 2001-04-16 | 2009-04-21 | Panacea Pharmaceuticals, Inc. | Methods of treating prion disease in mammals |
| GB0201882D0 (en) * | 2002-01-28 | 2002-03-13 | Novartis Ag | Organic compounds |
| CA2493253A1 (fr) * | 2002-08-01 | 2004-02-12 | Neurosearch A/S | Composes utilises dans le traitement de maladies sensibles a une therapie anti-angiogenetique |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US7326729B2 (en) * | 2004-05-12 | 2008-02-05 | Schering Corporation | CXCR1 and CXCR2 chemokine antagonists |
| TW200600492A (en) * | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| EP1809619A1 (fr) | 2004-10-21 | 2007-07-25 | Transtech Pharma, Inc. | Composes bissulfonamide utilises en tant qu'agonistes du galr1, compositions, et procedes d'utilisation associes |
| ATE499370T1 (de) | 2005-01-19 | 2011-03-15 | Bristol Myers Squibb Co | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen |
| WO2006089871A2 (fr) * | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Derives de diphenyluree utiles en tant qu'agents d'ouverture de canal erg pour le traitement d'arythmies cardiaques |
| DE602006017694D1 (de) | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
| US7714002B2 (en) | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| KR20080027890A (ko) | 2005-06-27 | 2008-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | 혈전성 증상의 치료에 유용한 ｐ2ｙ1 수용체의 ｎ-연결헤테로시클릭 길항제 |
| ATE502924T1 (de) | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| JP2008184403A (ja) * | 2007-01-29 | 2008-08-14 | Japan Health Science Foundation | 新規ｃ型肝炎ウイルス阻害剤 |
| KR100982661B1 (ko) * | 2008-04-22 | 2010-09-17 | 전남대학교산학협력단 | 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법 |
| KR100970940B1 (ko) * | 2010-05-03 | 2010-07-20 | 전남대학교산학협력단 | 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로 함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및 이를 이용한 말라리아 치료방법 |
| US10093617B1 (en) * | 2015-10-30 | 2018-10-09 | Sumitomo Chemical Company, Limited | Method for producing 2-amino-4-substituted phenol |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA921120B (en) * | 1991-02-19 | 1993-01-27 | Smithkline Beecham Corp | Cytokine inhibitors |
| JPH11503110A (ja) * | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体拮抗剤 |
| AU6035899A (en) * | 1998-09-18 | 2000-04-10 | Smithkline Beecham Corporation | Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis |
-
2000
- 2000-06-13 CO CO00043844A patent/CO5200760A1/es not_active Application Discontinuation
- 2000-06-14 AR ARP000102923A patent/AR030391A1/es not_active Application Discontinuation
- 2000-06-15 WO PCT/US2000/016499 patent/WO2000076495A1/fr not_active Ceased
- 2000-06-15 HK HK02106188.7A patent/HK1044483A1/zh unknown
- 2000-06-15 CZ CZ20014471A patent/CZ20014471A3/cs unknown
- 2000-06-15 HU HU0201571A patent/HUP0201571A3/hu unknown
- 2000-06-15 MX MXPA01013004A patent/MXPA01013004A/es unknown
- 2000-06-15 AU AU57413/00A patent/AU766083B2/en not_active Ceased
- 2000-06-15 JP JP2001502828A patent/JP2003501459A/ja not_active Withdrawn
- 2000-06-15 CN CN00809045A patent/CN1355697A/zh active Pending
- 2000-06-15 PL PL00352232A patent/PL352232A1/xx not_active Application Discontinuation
- 2000-06-15 TR TR2001/03680T patent/TR200103680T2/xx unknown
- 2000-06-15 EP EP00942843A patent/EP1185261A4/fr not_active Withdrawn
- 2000-06-15 NZ NZ514695A patent/NZ514695A/en unknown
- 2000-06-15 CA CA002377341A patent/CA2377341A1/fr not_active Abandoned
- 2000-06-15 KR KR1020017016142A patent/KR20020010709A/ko not_active Withdrawn
- 2000-06-15 IL IL14576100A patent/IL145761A0/xx unknown
- 2000-06-15 BR BR0010802-2A patent/BR0010802A/pt not_active IP Right Cessation
-
2001
- 2001-11-16 ZA ZA200109479A patent/ZA200109479B/en unknown
- 2001-12-11 NO NO20016053A patent/NO20016053L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000076495A1 (fr) | 2000-12-21 |
| JP2003501459A (ja) | 2003-01-14 |
| IL145761A0 (en) | 2002-07-25 |
| BR0010802A (pt) | 2002-02-19 |
| CZ20014471A3 (cs) | 2002-08-14 |
| AR030391A1 (es) | 2003-08-20 |
| AU5741300A (en) | 2001-01-02 |
| MXPA01013004A (es) | 2002-07-30 |
| CA2377341A1 (fr) | 2000-12-21 |
| EP1185261A4 (fr) | 2004-02-25 |
| NZ514695A (en) | 2004-05-28 |
| HUP0201571A2 (en) | 2002-08-28 |
| TR200103680T2 (tr) | 2002-07-22 |
| CN1355697A (zh) | 2002-06-26 |
| EP1185261A1 (fr) | 2002-03-13 |
| ZA200109479B (en) | 2002-11-18 |
| HK1044483A1 (zh) | 2002-10-25 |
| NO20016053D0 (no) | 2001-12-11 |
| HUP0201571A3 (en) | 2002-11-28 |
| KR20020010709A (ko) | 2002-02-04 |
| PL352232A1 (en) | 2003-08-11 |
| NO20016053L (no) | 2001-12-11 |
| AU766083B2 (en) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5200760A1 (es) | Antagonistas del receptor de la il-8 ceptor il-8 | |
| CO5280059A1 (es) | Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones | |
| CO5160294A1 (es) | Composicion farmaceutica que inhibe o detiene el crecimiento de virus en animales particularmente mamiferos sarrollo de virus en animales y composiciones farmaceuticas que los contienen | |
| AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
| PE20020254A1 (es) | Derivados de piridina | |
| AR015425A1 (es) | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion | |
| CO4990929A1 (es) | Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8 | |
| UY26093A1 (es) | Inhibidores de ap2 de bifenilos que contienen compuestos heterociclicos y metodo | |
| AR032398A1 (es) | Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion | |
| DK1485359T3 (da) | Natriumkanalblokkere | |
| CO5140088A1 (es) | Derivados de fenil y piridinil amida, su procedimiento de sintesis y composiciones farmaceuticas que los contienen | |
| CO5130004A1 (es) | 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas | |
| AR008290A1 (es) | Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios. | |
| AR033803A1 (es) | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas | |
| BG102214A (en) | Derivatives of azetidinons for the treatment of atherosclerosis | |
| BR0311315A (pt) | Sulfonas aromáticas e sua utilização médica | |
| AR037940A1 (es) | Compuestos antivirales de piridoquinoxalina | |
| CO5261594A1 (es) | Inhibidores de myt1 cinasa | |
| AR008331A1 (es) | Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen | |
| CO5170514A1 (es) | Antagonistas de los receptores de la il-8 nistas del receptor de la il-8 | |
| CO5190710A1 (es) | Antagonistas de un receptor de il-8 un receptor de il-8 | |
| ATE320480T1 (de) | Von der seebarsch epinephelus coioides derivierte unsterbliche zellinie und ihre verwendungen | |
| CO5271703A1 (es) | Compuestos quimicos | |
| CO5190712A1 (es) | Antagonistas de los receptores de la il-8 de los receptores de la il-8 | |
| CO5170528A1 (es) | Antagonistas de los receptores de la il-8 nistas del recpetor de la il-8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |